Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mDOT for Hydroxyurea Adherence in Sickle Cell Anemia
NCT02844673Phase 2Completed
- Sponsor
- Muhimbili University of Health and Allied Sciences
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hydroxyurea in sickle cell anemia (SCA), sponsored by Muhimbili University of Health and Allied Sciences. Primary endpoint: Medication Possession Ratio >= 80% at 3 months. Started Apr 2017; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT02844673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844673.